NARMAFOTINIB Large-Scale Manufactre Complete

Core Insights - Amplia Therapeutics has successfully completed the first large-scale manufacture of narmafotinib, producing approximately 13 kg of the drug, marking a significant step towards Phase 3 readiness [1] - The transition from R&D to commercial manufacturing has been achieved, ensuring sufficient drug supply for ongoing pancreatic cancer trials and other planned studies [1][3] Manufacturing and Production - The company collaborated closely with its contract development and manufacturing organization (CDMO) to ensure a seamless transition to large-scale production, resulting in production efficiencies and significant cost savings [2] - The next step involves converting the 13 kg of active pharmaceutical ingredient (API) into oral capsules for clinical trials [2] Clinical Development - The newly manufactured API will support Amplia's pancreatic cancer trials and other studies currently in planning stages [3] - Dr. Rhiannon Jones emphasized the importance of this large-scale API synthesis campaign in preparing for the next stages of clinical development [4] Quality Standards - Narmafotinib is manufactured under Good Manufacturing Practice (GMP), ensuring that the product meets strict safety and quality requirements [4] Drug Information - Narmafotinib (AMP945) is a best-in-class inhibitor of the protein FAK, which is over-expressed in pancreatic cancer and is a significant target in solid tumors [6] - The drug has shown promising results in preclinical studies and is currently undergoing clinical trials, including the ACCENT trial, which has achieved a confirmed response rate of 35% [7]